Preview Mode Links will not work in preview mode

Jun 24, 2019

Video proceedings from the first in a series of 6 integrated symposia held at the 2019 ONS Annual Congress. Featuring perspectives from Ms Jessica Mitchell, Dr Eileen M O’Reilly, Dr Philip A Philip and Ms Amanda Wagner.

  • Introduction 0m0s
    • Program overview: Dr Love
  • Colorectal Cancer (CRC) (5:43)
  • Case (Ms Wagner): A man in his mid-70s with metastatic appendiceal carcinoma who received third-line TAS-102 after disease progression on FOLFIRI/bevacizumab and FOLFOX/bevacizumab (8:11)
  • Case (Ms Mitchell): A man in his early 40s with MSI-high metastatic CRC who experienced a dramatic response to pembrolizumab (29:59)
  • Hepatocellular Carcinoma (HCC) (36:14)
  • Case (Ms Wagner): A man in his mid-40s with metastatic HCC who developed hand-foot syndrome while receiving sorafenib (38:21)
  • Case (Ms Mitchell): A woman in her mid-60s with metastatic HCC who had a good response to nivolumab but developed arthralgias (58:07)
  • Pancreatic Cancer (1:04:33)
  • Case (Ms Mitchell): A woman in her mid-70s with locally advanced pancreatic cancer who received neoadjuvant FOLFIRINOX (1:04:47)
  • Case (Ms Wagner): A man in his mid-60s with metastatic pancreatic cancer who received nab paclitaxel/gemcitabine and nal-IRI (1:12:13)
  • Gastroesophageal Cancers (1:20:20)
  • Case (Ms Wagner): A man in his early 70s with metastatic esophageal adenocarcinoma who received FOLFOX followed by paclitaxel/ramucirumab upon disease progression (1:20:43)
  • Case (Ms Mitchell): A woman in her early 60s with metastatic gastric cancer who experienced an excellent response to pembrolizumab but developed autoimmune hypothyroidism (1:24:02)

Select publications